MedTrace Logo

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

NCT02950922 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2018-08-06

No results posted yet for this study

Summary

This is a multi-center, randomized, vehicle-controlled, double-blind Phase 2 study in adults and adolescent subjects with mild to moderate atopic dermatitis.

Conditions

Interventions

DRUG

RVT-501 0.2% ointment

DRUG

RVT-501 0.5% ointment

OTHER

Vehicle ointment

Placebo comparator

Sponsors & Collaborators

  • Dermavant Sciences GmbH

    lead INDUSTRY

Principal Investigators

  • James Lee, MD, PhD · Dermavant Sciences, Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-07-03
Completion
2017-07-03

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02950922 on ClinicalTrials.gov